New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the Decipher Prostate genomic classifier. The findings, which will be shared for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest...
